Development of immune-related adverse events is associated with improved survival outcomes in cancer patients receiving immune checkpoint inhibitors
Immune checkpoint inhibitors (ICIs) have become the standard-of-care in various cancer types. However, treatment with ICIs occasionally cause immune-related adverse events (irAEs). This study assessed the incidence and clinical features of irAEs and ex…